Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) announced today that it had begun the sale of its generic version of Pfizer's Zoloft (Sertraline) Tablets, 25 mg, 50 mg, and 100 mg in the US.
Teva has been awarded a 180-day period of marketing exclusivity for this product.
Teva's AB-rated Sertraline Tablets are indicated for treatment of major depressive disorder.
On the basis of IMS data, Teva says that sales of the brand product in the US were approximately $3.1 billion for the twelve months ended June 2006.
Pfizer is expected to market its own authorized generic version of Zoloft.
This is the second time in a month that Teva has launched a generic version of a blockbuster drug. Last month, the company started to sell its generic version of Merck's high cholesterol treatment Zocor.
Since reaching a low for the year on July 21, Teva's share price has risen 16%. The share is currently at $34.80 on Nasdaq, giving the company a market cap of $26.61 billion.
Published by Globes [online], Israel business news - www.globes.co.il - on August 14, 2006
© Copyright of Globes Publisher Itonut (1983) Ltd. 2006.